Mindset Pharma Files Patents for Nonhallucinogenic Psychedelic Drugs to Treat Brain Disorders

Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) filed patent applications in multiple countries for a group of compounds called “Family 6” that are not hallucinogenic and are designed to be better versions of existing psychedelic and nonpsychedelic drugs, according to a statement from the company.

By making the drugs nonhallucinogenic, the company aims to help a larger group of people, including children and older adults, as these drugs won’t cause the mind-altering effects often associated with psychedelics.

This would also make treatment more convenient, as patients wouldn’t need to be supervised during treatment.

“By reducing or removing the psychedelic effect, in-clinic supervision should not be necessary, in turn reducing cost and improving convenience of these treatment options,” CEO James Lanthier said in a statement.

“They’re going to work better as (mental-health) medicines; they’ll be safer, more predictable, have potentially different durations,” he added.

With multiple psychedelic drug candidates advancing well, @MindsetPharma is now making a major discovery push into novel non-hallucinogenic drugs. We are excited about the patient groups and indications that this class of drugs can potentially serve. https://t.co/XAITRcgXrq

— James Lanthier (@JamesLanthier) March 28, 2023

The company has completed pre-clinical studies on the non-tryptamine compounds from Family 6, which have shown positive results. The drugs have been tested in several ways, including in-vitro screening, ADME evaluation, and in vivo studies, to assess their benefits and safety before moving to clinical trials.

In-vitro screening: Laboratory tests conducted in a controlled environment outside a living organism, like in a test tube or petri dish. ADME: Evaluating how the drug is absorbed, distributed, metabolized, and excreted by the body. In vivo studies: Tests performed on living organisms, such as animals, to understand how the drug works in a real-life situation.

The compounds have been found to activate the 5-HT2A serotonin receptor without causing hallucinations. This receptor is involved in various brain functions and has been a target for treating neuropsychiatric and neurological disorders. The compounds can interact with this receptor without creating the unwanted side effects that hallucinogenic drugs typically cause.

Some Family 6 compounds are more potent than psilocybin and 5-MeO-DMT as 5-HT2A agonists, but these drug candidates elicited only a modest or no head twitch response, suggesting a non-hallucinogenic effect profile.

The patent applications will protect Mindset’s rights to its nonhallucinogenic non-tryptamine compounds from Family 6, a significant step toward its goal to develop new medicines to help people with brain-related disorders for which there are currently no true effective treatments.